8-K filing — Lifeward Ltd. (LFWD)
Filed: 2026-08-31 AccNo: 0001178913-26-004360 Size: 206 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stocks · News reference
Lifeward Q2 Adj. EPS $(1.46) Misses $(1.34) Estimate, Sales $6.623M Beat $6.530M Estimate
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.34) by 8.96 percent. This is a 61.07 percent increase over losses of $(3.75) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lifeward Appoints Josh Hexter As Interim CEO, Succeeding Mark Grant, Effective September 1; Names Rami Aviram CFO Effective November 1
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today
Lifeward Launches Six-Mointh Pilot Program With Ottobock Care To Enable Greater Patient Access To Its ReWalk 7 Personal Exoskeleton
The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’s established clinical expertise and regional patient care infrastructure. Through the pilot, the companies intend to